Orris

Olfactory neuroblastoma

Reading File
Finding Sources
Finding Sources
Searching PubMed

olfactory neuroblastoma esthesioneuroblastoma

Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
Loading Image
I now have comprehensive data from multiple authoritative textbooks. Let me compile the full answer.

Olfactory Neuroblastoma (Esthesioneuroblastoma)

Definition and Origin

Olfactory neuroblastoma (ONB) - also called esthesioneuroblastoma - is a rare malignant neuroectodermal tumor arising from the specialized olfactory mucosa of the upper nasal cavity. It accounts for less than 5% of all sinonasal malignancies, with an incidence of approximately 4 cases per million population.
The tumor arises specifically from the superior nasal cavity - including the superior turbinate, cribriform plate, and upper third of the nasal septum.
  • Cummings Otolaryngology; Scott-Brown's Otorhinolaryngology

Epidemiology

  • Bimodal age distribution: peaks in the 2nd and 6th decades
  • No sex or racial predilection
  • ~50% of cases present as Kadish stage C (advanced disease)

Clinical Presentation

FeatureFrequency
Nasal obstruction70%
Epistaxis46%
AnosmiaVariable
On examination: a reddish-gray, soft, polypoidal, highly vascular mucosa-covered mass in the olfactory groove.
  • K.J. Lee's Essential Otolaryngology; Scott-Brown's

Histopathology

ONB is a small round blue cell tumor - morphologically similar to lymphoma, small cell carcinoma, Ewing sarcoma, PNET, rhabdomyosarcoma, and retinoblastoma. Key distinguishing features:
Architecture:
  • Well-circumscribed nests and lobules separated by fibrovascular stroma
  • Fibrillary matrix (tangled neuronal cell processes / neuropil)
  • Homer-Wright pseudorosettes: tumor cells mantling solid fibrillary neuropil stroma (characteristic)
  • Flexner-Wintersteiner rosettes: cells surrounding an empty pseudolumen
  • Perivascular rosettes may also occur
Cytology: Uniform small round cells with small nuclei, scant cytoplasm, and finely stippled ("salt and pepper") chromatin
Immunohistochemistry:
  • Positive: synaptophysin, chromogranin, INSM1, CD56, neuron-specific enolase (NSE), S-100 protein
  • Negative: cytokeratin (helps distinguish from carcinoma)
  • No single pathognomonic marker exists
Histological image (H&E, Grade I/II ONB - Homer-Wright pseudorosettes with fibrillary neuropil):
Grade I/II Olfactory Neuroblastoma - Homer-Wright pseudorosettes
  • Robbins, Cotran & Kumar Pathologic Basis of Disease; Scott-Brown's

Hyams' Grading System

The Hyams system divides ONB into four histological grades (I-IV). Grades I and II (better-differentiated) are sometimes specifically called "aesthesioneuroblastoma." Higher grades show more mitoses, less neuropil, and necrosis.

Staging: Modified Kadish System

StageDescription
ATumor confined to the nasal fossa
BExtension to the paranasal sinuses
CExtension beyond the nasal cavity/paranasal sinuses
DCervical lymphadenopathy or distant metastasis (modified system)
~50% of patients present at Stage C.
  • K.J. Lee's Essential Otolaryngology; Cummings Otolaryngology

Metastasis

  • Locoregional (cervical) metastasis: 5% at presentation; up to 20-25% lifetime; ~60% of neck metastases appear within 6 months of diagnosis
  • Distant metastasis: lung and bone
  • Late recurrences can occur more than a decade after initial treatment, necessitating long-term follow-up
Local recurrence 29%, regional recurrence 16%, distant recurrence 17% (meta-analysis by Dulguerov et al.).

Management

ONB is typically radiosensitive. Best outcomes come from multimodality therapy.

Surgery

  • Standard approach: craniofacial resection (open) or increasingly endoscopic resection
  • A 2025 systematic review in Frontiers in Oncology comparing endoscopic vs. open approaches found equivalent oncologic outcomes with lower morbidity for endoscopic surgery
  • Endoscopic surgery is associated with earlier Kadish stage and improved survival even after accounting for publication year (Devaiah & Andreoli meta-analysis, 23 series, 361 patients)

Radiation Therapy

  • Combined surgery + RT is superior to either modality alone
  • Surgery + RT: 73% 5-year OS vs. 68% surgery alone vs. 35% RT alone (SEER database)
  • Surgery + RT improves survival by ~20% over surgery alone
  • Postoperative RT dose: 50-65 Gy; IMRT/proton beam preferred for sparing orbital/intracranial structures
  • Elective neck irradiation is favored over surgery for the N0 neck given the risk of high Level II and retropharyngeal nodal failures

Chemotherapy

  • Added for Stage C disease
  • Regimens: cisplatin, cyclophosphamide, etoposide, doxorubicin, vincristine
  • Some centers use preoperative chemoradiotherapy (50 Gy ± cyclophosphamide/vincristine) to reduce tumor burden before surgery - reported 5- and 10-year survival 81% and 54.5% respectively (Polin et al., 34 patients)
  • Palliative chemotherapy for intracranial metastases: modest efficacy, median survival 10.5 months
  • Cummings Otolaryngology, p. 2277

Prognosis

StageApproximate 5-year Survival
A/B (Stage-limited)92% (craniofacial resection)
C50-70%
Overall range40-90% (surgery + RT + chemo)
Genetic changes are heterogeneous, with varying chromosomal gains/losses across cases.

Recent Evidence

Three recent systematic reviews (2024-2025) confirm:
  1. Endoscopic vs. open approaches (Koch et al., 2025): endoscopic surgery achieves comparable oncologic control with reduced morbidity
  2. Olfaction preservation with unilateral endoscopic resection (Rodas et al., 2024): promising results for preserving smell in select patients
  3. Combined surgery + radiation remains the evidence-based standard of care per current literature
This is a shared conversation. Sign in to Orris to start your own chat.